Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCK | P27707 | 17/20 | 0.59 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | UBE2M | P61081 | 1/20 | 0.39 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10172500 | 0.80 | DCK (0.47) | DCK | |
| SCHEMBL14163233 | 0.79 | UBE2M (0.46) | UBE2MDCUN1D1 | |
| SCHEMBL311117 | 0.77 | DCK (0.51) | DCKATR | |
| SCHEMBL10172442 | 0.77 | DCK (0.48) | DCKUBE2MDCUN1D1 | |
| SCHEMBL310866 | 0.71 | DCK (0.56) | DCK | |
| SCHEMBL312504 | 0.69 | DCK (0.49) | DCK | |
| SCHEMBL10172438 | 0.69 | GPR119 (0.50) | DCK | |
| SCHEMBL10172453 | 0.68 | DCK (0.48) | DCK | |
| SCHEMBL311256 | 0.63 | DCK (0.73) | DCK | |
| SCHEMBL10172488 | 0.62 | DCK (0.53) | DCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093246-B2 | potent deoxycytidine kinase inhibitors; O-linked pyrimidin-4-amine-based compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093246-B2 | potent deoxycytidine kinase inhibitors; O-linked pyrimidin-4-amine-based compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093246-B2 | potent deoxycytidine kinase inhibitors; O-linked pyrimidin-4-amine-based compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080146571-A1 | O-LINKED PYRIMIDIN-4-AMINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE TO TREAT CANCER | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-06-19 | — | — | US | disclosed |
| US-20080146571-A1 | O-LINKED PYRIMIDIN-4-AMINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE TO TREAT CANCER | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-06-19 | — | — | US | disclosed |
| US-20080146571-A1 | O-LINKED PYRIMIDIN-4-AMINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE TO TREAT CANCER | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146571-A1 | O-LINKED PYRIMIDIN-4-AMINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE TO TREAT CANCER | DPYD, DHFR, TYMP | DCK 46/4885ATR 1007/4885SLC2A1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.